Auris Medical Holding AG Stock Price, News & Analysis (NASDAQ:EARS)

$0.81 0.01 (1.25 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$0.80
Today's Range$0.77 - $0.82
52-Week Range$0.60 - $1.50
Volume1.12 million shs
Average Volume393,179 shs
Market Capitalization$35.91 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86

About Auris Medical Holding AG (NASDAQ:EARS)

Auris Medical Holding AG logoAuris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:EARS
  • CUSIP: N/A
  • Web: www.aurismedical.com
Debt:
  • Debt-to-Equity Ratio: 1.43%
  • Current Ratio: 2.56%
  • Quick Ratio: 2.56%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $0.42 per share
  • Price / Book: 1.93
Profitability:
  • Trailing EPS: ($0.73)
  • Net Income: ($31,130,000.00)
  • Return on Equity: -218.83%
  • Return on Assets: -75.79%
Misc:
  • Employees: 24
  • Outstanding Shares: 44,330,000
 
Frequently Asked Questions for Auris Medical Holding AG (NASDAQ:EARS)

What is Auris Medical Holding AG's stock symbol?

Auris Medical Holding AG trades on the NASDAQ under the ticker symbol "EARS."

How were Auris Medical Holding AG's earnings last quarter?

Auris Medical Holding AG (NASDAQ:EARS) announced its quarterly earnings results on Thursday, May, 11th. The biotechnology company reported ($0.22) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.08. View Auris Medical Holding AG's Earnings History.

When will Auris Medical Holding AG make its next earnings announcement?

Auris Medical Holding AG is scheduled to release their next quarterly earnings announcement on Tuesday, November, 28th 2017. View Earnings Estimates for Auris Medical Holding AG.

Where is Auris Medical Holding AG's stock going? Where will Auris Medical Holding AG's stock price be in 2017?

2 brokers have issued 12 month target prices for Auris Medical Holding AG's stock. Their predictions range from $4.00 to $5.00. On average, they anticipate Auris Medical Holding AG's share price to reach $4.50 in the next twelve months. View Analyst Ratings for Auris Medical Holding AG.

What are Wall Street analysts saying about Auris Medical Holding AG stock?

Here are some recent quotes from research analysts about Auris Medical Holding AG stock:

  • 1. According to Zacks Investment Research, "Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. " (10/11/2017)
  • 2. Needham & Company LLC analysts commented, "EARS reported 4Q16 financials and update its three ongoing development programs. The next key data catalyst for EARS will be ph 3 HEALOS results for AM-111 (hearing loss) in 3Q17. The study, which should complete enrollment in 2Q17, is the first of two AM-111 pivotal studies in hearing loss. The Keyzilen program will first report results from the open-label studies (AMPACT-1 and 2) in 2Q17 while the recently modified TACCT3 study is on track to have top-line results in 1Q18. EARS plans to evaluate AM-125 (Meniere's disease/vertigo) in an additional ph 1 trial (initiating in 2H17) prior to discussing a regulatory pathway with regulatory authorities. The current EARS market valuation appears to place minimal to no value on any of the ongoing clinical programs.We maintain our Buy rating and adjust our $PT to $4 (from $5)." (3/14/2017)

Are investors shorting Auris Medical Holding AG?

Auris Medical Holding AG saw a increase in short interest during the month of October. As of October 13th, there was short interest totalling 960,301 shares, an increase of 29.7% from the September 29th total of 740,577 shares. Based on an average daily volume of 442,722 shares, the short-interest ratio is currently 2.2 days. Approximately 4.0% of the company's stock are sold short.

Who are some of Auris Medical Holding AG's key competitors?

Who are Auris Medical Holding AG's key executives?

Auris Medical Holding AG's management team includes the folowing people:

  • Thomas Meyer, Chairman of the Board, Chief Executive Officer (Age 48)
  • Hernan Levett, Chief Financial Officer
  • Anne Sabine Zoller, General Counsel (Age 36)
  • Cindy McGee, Head of Investor Relations and Corporate Communications
  • Andrea Braun, Head of Regulatory and Quality Affairs
  • Thomas Jung M.D., Ph.D., Chief Development Officer
  • Bettina Mirella Stubinski, Chief Medical Officer (Age 49)
  • James I. Healy M.D. Ph.D., Non-Executive Independent Vice Chairman of the Board (Age 52)
  • Wolfgang Arnold, Non-Executive Independent Director (Age 74)
  • Oliver Kubli, Non-Executive Independent Director (Age 43)

How do I buy Auris Medical Holding AG stock?

Shares of Auris Medical Holding AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Auris Medical Holding AG's stock price today?

One share of Auris Medical Holding AG stock can currently be purchased for approximately $0.81.

How big of a company is Auris Medical Holding AG?

Auris Medical Holding AG has a market capitalization of $35.91 million. The biotechnology company earns ($31,130,000.00) in net income (profit) each year or ($0.73) on an earnings per share basis. Auris Medical Holding AG employs 24 workers across the globe.

How can I contact Auris Medical Holding AG?

Auris Medical Holding AG's mailing address is Bahnhofstrasse 21, ZUG, ZUG 6300, Switzerland. The biotechnology company can be reached via phone at +41-41-7297194 or via email at [email protected]


MarketBeat Community Rating for Auris Medical Holding AG (NASDAQ EARS)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  162
MarketBeat's community ratings are surveys of what our community members think about Auris Medical Holding AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Auris Medical Holding AG (NASDAQ:EARS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.50 (455.56% upside)
Consensus Price Target History for Auris Medical Holding AG (NASDAQ:EARS)
Price Target History for Auris Medical Holding AG (NASDAQ:EARS)
Analysts' Ratings History for Auris Medical Holding AG (NASDAQ:EARS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/1/2017Roth CapitalReiterated RatingBuy$5.00LowView Rating Details
3/14/2017Needham & Company LLCLower Price TargetBuy$5.00 -> $4.00HighView Rating Details
11/11/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
6/15/2016Leerink SwannReiterated RatingBuy$12.00N/AView Rating Details
6/10/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Auris Medical Holding AG (NASDAQ:EARS)
Earnings by Quarter for Auris Medical Holding AG (NASDAQ:EARS)
Earnings History by Quarter for Auris Medical Holding AG (NASDAQ EARS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/28/2017($0.20)N/AView Earnings Details
8/10/20176/30/2017($0.21)($0.12)ViewN/AView Earnings Details
5/11/20173/31/2017($0.14)($0.22)ViewN/AView Earnings Details
3/14/201712/31/2016($0.29)($0.16)ViewN/AView Earnings Details
11/10/2016Q316($0.28)($0.23)ViewListenView Earnings Details
5/11/2016Q116($0.23)($0.26)ViewListenView Earnings Details
3/14/2016Q415($0.29)($0.16)ViewListenView Earnings Details
11/12/2015Q315($0.28)($0.16)ViewListenView Earnings Details
8/19/2015Q215($0.23)($0.36)ViewListenView Earnings Details
5/28/2015Q115($0.22)($0.29)ViewListenView Earnings Details
3/19/2015Q4($0.23)($0.17)ViewListenView Earnings Details
12/3/2014Q3($0.24)($0.14)ViewN/AView Earnings Details
9/15/2014Q2 2014($0.34)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Auris Medical Holding AG (NASDAQ:EARS)
Current Year EPS Consensus Estimate: $-0.68 EPS
Next Year EPS Consensus Estimate: $-0.29 EPS

Dividends

Dividend History for Auris Medical Holding AG (NASDAQ:EARS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Auris Medical Holding AG (NASDAQ EARS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Auris Medical Holding AG (NASDAQ:EARS)
Latest Headlines for Auris Medical Holding AG (NASDAQ EARS)
Source:
DateHeadline
Are You Keeping An Eye On EARS And 6 Other Pharma Stocks?Are You Keeping An Eye On EARS And 6 Other Pharma Stocks?
www.rttnews.com - November 17 at 12:45 PM
Auris Medical: Clinical Updates and Potential CatalystsAuris Medical: Clinical Updates and Potential Catalysts
finance.yahoo.com - November 10 at 11:44 AM
-$0.20 EPS Expected for Auris Medical Holding AG (EARS) This Quarter-$0.20 EPS Expected for Auris Medical Holding AG (EARS) This Quarter
www.americanbankingnews.com - November 9 at 9:22 PM
What You Must Know About Auris Medical Holding AG’s (EARS) Financial StrengthWhat You Must Know About Auris Medical Holding AG’s (EARS) Financial Strength
finance.yahoo.com - November 9 at 1:20 AM
Auris Medical Holding AG (EARS) Scheduled to Post Quarterly Earnings on WednesdayAuris Medical Holding AG (EARS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:06 AM
Short Interest in Auris Medical Holding AG (EARS) Grows By 29.7%Short Interest in Auris Medical Holding AG (EARS) Grows By 29.7%
www.americanbankingnews.com - October 28 at 1:26 AM
Auris Medical Holding AG (EARS) Expected to Announce Earnings of -$0.20 Per ShareAuris Medical Holding AG (EARS) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - October 21 at 2:20 AM
Edited Transcript of EARS earnings conference call or presentation 14-Mar-16 12:00pm GMTEdited Transcript of EARS earnings conference call or presentation 14-Mar-16 12:00pm GMT
finance.yahoo.com - October 16 at 3:25 AM
Corporate News Blog - Auris Medical Executes Two Share Purchase Agreements with Lincoln Park Capital FundCorporate News Blog - Auris Medical Executes Two Share Purchase Agreements with Lincoln Park Capital Fund
finance.yahoo.com - October 13 at 6:38 PM
BRIEF-Auris Medical Holding AG files for resale of up to 7.2 mln common sharesBRIEF-Auris Medical Holding AG files for resale of up to 7.2 mln common shares
www.reuters.com - October 12 at 6:54 PM
Auris Medical Holding (EARS) Reports Two Share Purchase Agreements for up to $15M with Lincoln Park Capital Fund - StreetInsider.comAuris Medical Holding (EARS) Reports Two Share Purchase Agreements for up to $15M with Lincoln Park Capital Fund - StreetInsider.com
www.streetinsider.com - October 12 at 5:42 AM
Zacks Investment Research Downgrades Auris Medical Holding AG (EARS) to HoldZacks Investment Research Downgrades Auris Medical Holding AG (EARS) to Hold
www.americanbankingnews.com - October 11 at 11:02 PM
BRIEF-Auris Medical announces share purchase agreements with Lincoln Park Capital FundBRIEF-Auris Medical announces share purchase agreements with Lincoln Park Capital Fund
www.reuters.com - October 11 at 7:38 PM
Auris Medical Holding (EARS) Reports Two Share Purchase Agreements for up to $15M with Lincoln Park Capital FundAuris Medical Holding (EARS) Reports Two Share Purchase Agreements for up to $15M with Lincoln Park Capital Fund
www.streetinsider.com - October 11 at 7:38 PM
Auris Medical Announces Transfer to Nasdaq Capital MarketAuris Medical Announces Transfer to Nasdaq Capital Market
www.nasdaq.com - September 28 at 9:05 AM
BRIEF-Auris Medical provides board of directors updateBRIEF-Auris Medical provides board of directors update
www.reuters.com - September 28 at 12:08 AM
Auris Medical Provides Board of Directors Update - GlobeNewswire (press release)Auris Medical Provides Board of Directors Update - GlobeNewswire (press release)
globenewswire.com - September 27 at 7:07 PM
Auris Medical Provides Board of Directors UpdateAuris Medical Provides Board of Directors Update
feeds.benzinga.com - September 26 at 9:34 AM
Opdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches EyesOpdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches Eyes
www.rttnews.com - September 25 at 11:37 AM
Auris Medical Holding AG (EARS) versus Catalyst Pharmaceuticals (CPRX) Financial ContrastAuris Medical Holding AG (EARS) versus Catalyst Pharmaceuticals (CPRX) Financial Contrast
www.americanbankingnews.com - September 24 at 6:20 PM
BRIEF-Auris Medical completes patient recruitment for phase 3 trial of Keyzilen in acute and post-acute tinnitusBRIEF-Auris Medical completes patient recruitment for phase 3 trial of Keyzilen in acute and post-acute tinnitus
www.reuters.com - September 22 at 5:10 PM
Auris Medical Holding (EARS) Reports Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen - StreetInsider.comAuris Medical Holding (EARS) Reports Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen - StreetInsider.com
www.streetinsider.com - September 22 at 8:46 AM
Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute TinnitusAuris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute Tinnitus
finance.yahoo.com - September 22 at 8:46 AM
Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27Auris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27
finance.yahoo.com - September 20 at 7:00 PM
Why Auris Medical Holding AG (EARS) Could Be A BuyWhy Auris Medical Holding AG (EARS) Could Be A Buy
finance.yahoo.com - September 15 at 11:43 PM
Auris Medical to Host Scientific Symposium at the AAO-HNSF ... - GlobeNewswire (press release)Auris Medical to Host Scientific Symposium at the AAO-HNSF ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 5:51 AM
Auris Medical to Host Scientific Symposium at the AAO-HNSF Annual MeetingAuris Medical to Host Scientific Symposium at the AAO-HNSF Annual Meeting
finance.yahoo.com - September 5 at 7:44 PM
Auris Medical Announces Receipt of Nasdaq Notice - GlobeNewswire (press release)Auris Medical Announces Receipt of Nasdaq Notice - GlobeNewswire (press release)
globenewswire.com - August 25 at 12:05 AM
Auris Medical short of listing Nasdaq listing requirement of minimum SEAuris Medical short of listing Nasdaq listing requirement of minimum SE
seekingalpha.com - August 24 at 7:02 PM
Auris Medical Announces Receipt of Nasdaq NoticeAuris Medical Announces Receipt of Nasdaq Notice
finance.yahoo.com - August 24 at 7:02 PM
Edited Transcript of EARS earnings conference call or presentation 10-Aug-17 12:00pm GMTEdited Transcript of EARS earnings conference call or presentation 10-Aug-17 12:00pm GMT
finance.yahoo.com - August 11 at 6:37 PM
Auris Medical Provides Business Update and Reports Second ... - GlobeNewswire (press release)Auris Medical Provides Business Update and Reports Second ... - GlobeNewswire (press release)
globenewswire.com - August 11 at 12:26 AM
Auris Medical Holding AG (EARS) Releases Quarterly  Earnings ResultsAuris Medical Holding AG (EARS) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 10 at 7:46 PM
Auris Medical Provides Business Update and Reports Second Quarter 2017 Financial ResultsAuris Medical Provides Business Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 7:24 PM
Auris reports 2Q lossAuris reports 2Q loss
finance.yahoo.com - August 10 at 7:24 PM
Auris Medical Provides Business Update and Reports Second Quarter 2017  Financial ResultsAuris Medical Provides Business Update and Reports Second Quarter 2017 Financial Results
feeds.benzinga.com - August 10 at 6:58 AM
Auris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on AugustAuris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August
www.nasdaq.com - August 4 at 6:22 PM
Auris Medical Holding AG (NASDAQ:EARS) to Release Quarterly Earnings on ThursdayAuris Medical Holding AG (NASDAQ:EARS) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - August 4 at 3:08 PM
Auris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017 - GlobeNewswire (press release)Auris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017 - GlobeNewswire (press release)
globenewswire.com - August 3 at 5:07 PM
Auris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017Auris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017
finance.yahoo.com - August 3 at 5:07 PM
Auris Medical Completes Acquisition of AM-125 Assets - GlobeNewswire (press release)Auris Medical Completes Acquisition of AM-125 Assets - GlobeNewswire (press release)
www.globenewswire.com - July 20 at 3:24 PM
Auris Medical Completes Acquisition of AM-125 AssetsAuris Medical Completes Acquisition of AM-125 Assets
finance.yahoo.com - July 20 at 3:24 PM
ARRY Working Its Way, Be All Ears For Auris, BGNE Inks Deal With CELGARRY Working Its Way, Be All Ears For Auris, BGNE Inks Deal With CELG
www.nasdaq.com - July 6 at 4:51 AM
Auris Medical Holding (EARS) Reports Complete Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden DeafnessAuris Medical Holding (EARS) Reports Complete Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness
www.streetinsider.com - July 6 at 4:51 AM
BRIEF-Auris Medical completes enrollment of phase 3 healos trial of am-111 for the treatment of sudden deafnessBRIEF-Auris Medical completes enrollment of phase 3 healos trial of am-111 for the treatment of sudden deafness
www.reuters.com - July 5 at 11:49 PM
Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness - GlobeNewswire (press release)Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness - GlobeNewswire (press release)
globenewswire.com - July 5 at 6:48 PM
Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden DeafnessAuris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness
finance.yahoo.com - July 5 at 6:47 PM
Auris Medical Holding AG (EARS) Coverage Initiated by Analysts at Roth CapitalAuris Medical Holding AG (EARS) Coverage Initiated by Analysts at Roth Capital
www.americanbankingnews.com - July 3 at 6:25 PM
Auris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris - GlobeNewswire (press release)Auris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris - GlobeNewswire (press release)
globenewswire.com - June 22 at 5:20 PM
Auris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris - NasdaqAuris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris - Nasdaq
www.nasdaq.com - June 22 at 10:13 AM

Social Media

Financials

Financials are not available for this stock.

Chart

Auris Medical Holding AG (NASDAQ EARS) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.